Canada Greenlights Blood Tests for Alzheimer's and Nerve Damage

TORONTO, ON – September 01, 2026 – Health Canada has approved two revolutionary blood tests poised to change how doctors diagnose and monitor Alzheimer's disease and other neurological conditions, marking a significant step forward for brain health in the country. The decision grants Class II Medical Device Licenses to Japan-based diagnostics leader Fujirebio for its Lumipulse G pTau 217 and Lumipulse G NfL assays.

These tests, which run on the company’s fully automated LUMIPULSE® G platform, can detect key biomarkers of Alzheimer’s disease and general nerve damage from a simple blood sample. This offers a less invasive, more accessible alternative to current diagnostic standards like spinal taps and expensive brain scans.

"The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V., in a statement. The approvals build on the assays' existing CE marking for use in Europe, signaling their established clinical validity.

A New Era for Neurological Diagnosis

For decades, a definitive diagnosis of neurodegenerative disease has been a long and arduous journey for patients. It often involves subjective cognitive tests, costly PET scans with limited availability, and invasive lumbar punctures to analyze cerebrospinal fluid (CSF). Fujirebio’s newly approved blood tests represent a paradigm shift.

The Lumipulse G pTau 217 Plasma assay measures a specific form of the tau protein that is considered a highly accurate indicator of the amyloid pathology underlying Alzheimer's disease. This gives clinicians a powerful tool to help confirm or rule out Alzheimer's in patients over 50 showing signs of cognitive decline, complementing other diagnostic evaluations. Its ability to identify the disease's signature pathology early can empower patients and doctors to plan care and explore treatment options sooner.

The second test, the Lumipulse G NfL Blood assay, measures neurofilament light chain (NfL), a protein released into the blood when nerve cells are damaged. While not specific to any single disease, NfL levels serve as a crucial barometer for neuro-axonal injury. This makes it invaluable for monitoring disease progression and treatment response across a wide range of conditions, from multiple sclerosis (MS) and Parkinson's disease to traumatic brain injury.

Neurologists see this as a game-changer for triaging patients. A primary care physician could use these tests to more effectively determine which patients need an urgent referral to a specialist, optimizing the use of Canada's strained neurological resources. However, experts caution that these tests are not a magic bullet. "The interpretation of NfL, in particular, requires careful consideration of the entire clinical picture and age-adjusted values," noted one clinical laboratory director not affiliated with the company. "It's a powerful piece of the puzzle, but it's not the whole puzzle."

Navigating a Crowded and Competitive Market

Fujirebio's entry into the Canadian market comes at a time of intense competition and innovation in the neurological diagnostics space. The global race to develop reliable, scalable blood tests for Alzheimer's has seen major players like Roche, Abbott, and Quanterix make significant strides. Roche recently gained FDA clearance in the U.S. for a similar pTau217 test, setting a competitive benchmark.

However, Fujirebio is positioning itself strategically. Its primary advantage is the LUMIPULSE® G, a fully automated immunoassay platform already established in laboratories worldwide. This existing infrastructure could accelerate adoption and help standardize testing across different healthcare settings. Rather than requiring labs to invest in entirely new systems, Fujirebio's tests can be integrated into existing workflows, a key factor for budget-conscious hospital administrators.

The company has also been aggressively strengthening its position through strategic acquisitions and partnerships. Its 2022 acquisition of ADx NeuroSciences bolstered its R&D capabilities in biomarker development, while ongoing collaborations with firms like Beckman Coulter and Abbott signal an open-model approach to expanding market reach. This strategy leverages its 75-year history in diagnostics and a deep portfolio that includes both CSF and blood-based markers, allowing it to offer a more comprehensive suite of tools to clinicians.

The Billion-Dollar Question: Access and Reimbursement

While the clinical and technological promise is clear, a significant red flag remains: who will pay for it? The most transformative medical technologies are only effective if patients can access them. In Canada's provincially managed healthcare system, the path to public reimbursement is often long and complex.

Currently, public health plans in provinces like Ontario and British Columbia do not typically cover the cost of similar advanced biomarker tests. Patients often must pay out-of-pocket, sometimes hundreds of dollars, or gain access through specialized memory clinics or research studies. This creates a potential two-tiered system where access to cutting-edge diagnostics is determined by a patient's ability to pay or their proximity to a major urban research center.

Advocates and healthcare economists will argue that public funding for these tests is a matter of cost-effectiveness. By providing an early and accurate diagnosis, these blood tests could reduce the immense downstream costs associated with misdiagnosis, unnecessary imaging, and delayed care planning. A simple blood test could prevent the need for a PET scan, which can cost thousands of dollars and is only available in a limited number of centers. The onus will be on Fujirebio and the medical community to provide health ministries with the evidence needed to justify broad reimbursement.

The Regulatory Roadmap and What's Next

The Health Canada Class II license signifies that the devices are considered medium-risk and have met the country's standards for safety and effectiveness. This approval paves the way for Fujirebio to commercialize its technology across the nation.

Looking ahead, the company's commitment to the neurology space appears unwavering. Fujirebio has already launched research-use-only (RUO) versions of other promising biomarkers, including sTREM2, which is linked to neuroinflammation, and a CSF version of the pTau 217 assay. These research-grade products often act as a precursor to future clinical diagnostic tests, indicating a robust pipeline and a long-term strategy to solidify its leadership in the field. This steady expansion suggests that the approvals in Canada are not just a single product launch, but another calculated step in a global plan to reshape the future of brain health diagnostics.